[Coraxan and atenolol: similarities and differences in correction of clinical and functional indices in therapy of patients with coronary heart disease].
The aim of the study was to estimate clinical and functional indices under stable course of coronary heart disease (CHD) against the background of therapy with coraxan and atenolol. 95 patients (70 males and 29 females, average age 52.3 +/- 4.5 years) were observed. Addition of coraxan and atenolol to the standard therapy in patients with CHD made possible to improve patients" quality of life; tolerance to physical exercises was increased, and myocardial ischemia daily duration (MIDD) and number of ischemia episodes were decreased. Under the course coraxan therapy it was detected growth of ejection fraction and improvement of heart diastolic function. MIDD decrease accompanied improvement of indices, characterizing heart electrical instability.
Tatarchenko
I P
IP
Pozdniakova
N V
NV
Kapelovich
V Iu
VIu
Biriuchenko
M V
MV
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D001262:Atenolol / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000319:Adrenergic beta-Antagonists; D001262:Atenolol